We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
With all complex clinical trials, MHRA’s top priority is the safety and wellbeing of the trial participants
Factsheet providing more information on the Commission on Human Medicines' independent report on the safety implications of proposed puberty blocker legislation.
Paper prepared by academics on COVID-19 diagnosis and mortality.
New roads, reservoirs, airports, and railways held up by lengthy legal challenges will be completed more quickly under new proposals announced by the Chancellor today (15 October), fast-tracking national renewal.
Proposal to make a permanent order to prevent new patients aged under 18 from beginning to take puberty blockers for the purposes of gender incongruence and/or gender dysphoria, under the care of private prescribers.
MHRA has raised new concerns around the PATHWAYS trial looking into the prescription of puberty blockers among young people with gender incongruence.
Independent report by the Commission on Human Medicines on the safety implications of a proposal to restrict the availability of puberty blockers for under 18s.
Do not include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).